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Abstract
 
Human immunodeficiency virus (HIV)-1 infection depends on multiple lateral interactions be-
tween the viral envelope and host cell receptors. Previous studies have suggested that these in-
teractions are possible because HIV-1 receptors CD4, CXCR4, and CCR5 partition in choles-
terol-enriched membrane raft domains. We generated CD4 partitioning mutants by
substituting or deleting CD4 transmembrane and cytoplasmic domains and the CD4
ectodomain was unaltered. We report that all CD4 mutants that retain raft partitioning mediate
HIV-1 entry and CD4-induced Lck activation independently of their transmembrane and cy-
toplasmic domains. Conversely, CD4 ectodomain targeting to a nonraft membrane fraction re-
sults in a CD4 receptor with severely diminished capacity to mediate Lck activation or HIV-1
entry, although this mutant binds gp120 as well as CD4wt. In addition, the nonraft CD4 mu-
tant inhibits HIV-1 X4 and R5 entry in a CD4
 
 
 
cell line. These results not only indicate that
HIV-1 exploits host membrane raft domains as cell entry sites, but also suggest new strategies
for preventing HIV-1 infection.
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Introduction
 
The plasma membrane is a specialized structure that channels
and integrates the information that flows continuously be-
tween a cell and its environment. The cell plasma mem-
brane also constitutes the initial barrier against infection by
intracellular pathogens. Contrary to the view of the plasma
membrane as a homogenous phospholipid backbone
loaded with proteins, it is now established that it is a highly
sophisticated structure assembled of distinct lipid domains
that functionally organize the proteins embedded in the bi-
layer. One of these microdomain types, termed rafts, is
formed by glycosphingolipids (GSL),
 
*
 
 sphingomyelin, and
cholesterol packaged in the external leaflet of the plasma
membrane (1). Due to the high melting point of lipids,
membrane rafts are in a rigid, ordered state (2). Rafts none-
theless retain substantial lateral and rotational mobility.
They are viewed as moving platforms of ordered mem-
brane-bearing proteins with a specific preference for this
lipid environment, such as glycosylphosphatidylinositol
(GPI)-anchored and double-acylated cytoplasmic proteins.
Rafts may function as devices to control membrane pro-
tein–protein interactions and several mechanisms can be
envisioned. First, it is reported that interactions occur pref-
erentially between proteins sharing identical lipid environ-
ments (3). Accordingly, the interaction of raft-associated
proteins with membrane nonraft proteins is very restricted
(4). Second, proteins initially segregated in distinct elemen-
tary raft units might be brought together by raft coales-
cence, which could generate supramolecular complexes of
raft-associated proteins in a single clustering event. For in-
stance, lateral cross-linking of GPI-anchored raft proteins
triggers raft-associated tyrosine kinase activation (2) even
though these two types of proteins cannot directly interact.
A third possibility is that a protein that initially partitions in
a nonraft membrane region might be recruited into a pre-
existing raft, enabling raft-dependent protein–protein in-
teractions. Therefore, raft domains may organize protein
interactions in time and space by regulating raft coalescence
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and/or controlling the recruitment of nonraft proteins to
these domains. Nevertheless, this scenario might be even
more complex as membrane protein segregation not only
between raft and nonraft domains, but also between dis-
tinct raft subtypes, influences lateral organization of the
plasma membrane (5).
The temporal and spatial control of protein interactions
at the plasma membrane regulates cell signaling integration
and pathogen infection of cells (6). CD4 takes part in these
two processes, as it participates in the integration of TCR
signaling by recruiting p56
 
lck 
 
and is also the primary HIV-1
cell surface receptor (7, 8). To perform these functions,
CD4 must interact laterally with the TCR for T cell activa-
tion and with members of the chemokine receptor family,
such as CXCR4 or CCR5, to mediate HIV-1 entry (9–
11). Chemokine receptors act as necessary coreceptors for
HIV-1 infection, as gp120 binding to CD4 is insufficient to
promote virus entry (12).
Although the role of rafts in CD4-mediated signaling is
well established (8), the importance of CD4 association
with rafts for HIV-1 entry remains a subject of debate (13).
HIV-1 entry is impeded after raft disruption by membrane
cholesterol sequestration (14–16). Favoring a role for rafts
in HIV-1 infection, the inhibition of GSL synthesis blocks
HIV-1 entry (17, 18). Cholesterol depletion experiments
have suggested that large CD4–gp120 coreceptor com-
plexes are the consequence of raft clustering initially in-
duced by HIV-1 binding to CD4 (14). Even assuming that
CD4 and CCR5 might be constitutively associated at the
cell surface (19), HIV–host membrane fusion is a coopera-
tive process requiring multiple CD4–gp120–CCR5 com-
plexes (20), which may be formed by lateral raft rearrange-
ments. Viral entry would thus be enabled if CD4 and
chemokine receptor partition into raft domains. Accord-
ingly, it has been reported that the HIV-1 coreceptors
CCR5 and CXCR4 partition and signal in rafts after
ligand- or gp120-induced clustering (5, 14, 21–23). A re-
cent report suggests, however, that raft domains may not
have a determinant role in HIV-1 infection (24). Accord-
ing to this latter interpretation, CD4 partitioning in non-
raft membranes would not affect HIV-1 entry. Con-
versely, if HIV-1 uses host raft membranes as entry sites,
CD4 partitioning into nonraft membranes would impede
viral infection.
Here, we analyzed these possibilities by generating CD4
mutants in the cytoplasmic and transmembrane domains.
These mutants shared the extracellular domain of the WT
CD4 form. We generated a CD4 mutant that partitions in
the nonraft plasma membrane fraction by replacing CD4
transmembrane and cytoplasmic domains with the trans-
membrane and a very short cytoplasmic tail from the low
density lipoprotein (LDL)-R. This CD4 mutant (CD4–
LDL) neither activates Lck after CD4 cross-linking nor
mediates HIV-1 entry, which are two independent CD4
functions. The failure of the CD4–LDL mutant to mediate
these processes is the sole consequence of CD4 extracellu-
lar domain localization in a nonraft membrane fraction, be-
cause a raft-associated CD4–GPI mutant that lacks trans-
 
membrane and cytoplasmic CD4 domains activates Lck and
mediates HIV-1 entry. Moreover, the nonraft CD4 mutant
prevents X4 and R5 HIV-1 strain infection of CD4
 
 
 
T
cells. These results highlight the fundamental role of mem-
brane rafts in regulating the protein–protein interactions
required for HIV-1 entry and suggest new strategies for
preventing HIV-1 infection.
 
Materials and Methods
 
Generation of CD4 Mutants.
 
Selected transmembrane amino
acids of WT CD4 were replaced with alanine by site-directed
mutagenesis (Stratagene). The synthetic oligonucleotide primer
pairs 5
 

 
-GCAGCCAATGGCCGCGGCTGCGGCGGGGGG-
CGTCGCCG-3
 
 
 
and 5
 

 
-CGGCGACGCCCCCCGCCGCAG-
CCGCGGCCATTGGCTGC-3
 
 
 
(CD4-4A374); 5
 

 
-CCCTGA-
TTGTGGCGGCGGCCGCCGCCGGCCTCCTG-3
 
 
 
and 5
 

 
-
CAGGAGGCCGGCGGCGGCCGCCGCCACAATCAGGG-3
 

 
(CD4-4A377); 5
 

 
-GGGGGCGTCGCCGGCGCCGCGGCT-
TTCATTGGGCTAGGC-3
 
 
 
and 5
 

 
-GCCTAGCCCAATGA-
AAGCCGCGGCGCCGGCGACGCCCCC-3
 
 
 
(CD4-3A383);
5
 

 
-CGCCGGCCTCCTGCTTGCCGCTGGGCTAGGCATC-3
 

 
and 5
 

 
-GATGCCTAGCCCAGCGGCAAGCAGGAGGCCG-
GCG-3
 
 
 
(CD4-2A386); 5
 

 
-CATTGGGCTAGGCGCCGCCG-
CCTGTGTCAGGTGCCGGC-3
 
 
 
and 5
 

 
-GCCGGCACCTG-
ACACAGGCGGCGGCGCCTAGCCCAATG-3
 
 
 
(CD4-3A391);
5
 

 
-GGGCTAGGCATCGCCGCCGCTGTCAGGTGCCGGC-
ACCG-3
 
 
 
and 5
 

 
-CGGTGCCGGCACCTGACAGCGGCG-
GCGATGCCTAGCCC-3
 
 
 
(CD4-3A392); 5
 

 
-TCTGTGTCA-
GGGCCCGGCACCGAAGGCG-3
 
 
 
and 5
 

 
-CGCCTTCGGT-
GCCGGGCCCTGACACAGA-3
 

 
 (CD4-C397A); and 5
 

 
-GG-
CTAGGCATCGCCGCCGCTGTCAGGGCCCGGCACCGA
AGGCGC-3
 
 
 
and 5
 

 
-GCGCCTTCGGTGCCGGGCCCTGA-
CAGCGGCGGCGATGCCTAGCC-3
 
 
 
(CD4-C394/7A) were
used to extend CD4 cDNA cloned in pCDNA-3.1 with Pfu-
Turbo DNA polymerase. The product was DpnI-treated to spe-
cifically digest the parental template. The resulting plasmids were
transformed in Epicurian Coli XL1-Blue supercompetent cells
and clones (Stratagene) containing the mutated CD4 cDNA se-
lected by sequencing.
To construct CD4 chimeras, the luminal CD4 domain was
cloned in HindIII/KpnI-digested pcDNA3.1A/myc/his (Invitro-
gen) by PCR using 5
 

 
-GCCAAGCTTATGAACCGGGG
AGTC-3
 
 
 
and 5
 

 
-AGAGGTACCCATTGGCTGCACCGG-3
 

 
to produce pCD4ext. A GPI consensus sequence was rescued
from the GFP-GPI using 5
 

 
-AAAGGTACCTATGATCCGC
GCCCA-3
 
 
 
and 5
 

 
-CCCGCGAATTCTTAAAGAACATT-3
 

 
and was cloned in KpnI/EcoRI-digested pCD4ext. To construct
CD4–LDL, transmembrane and juxtamembrane LDL-R were
rescued from LGFP-GT46 (both plasmids were provided by P.
Keller, Max Planck Institute of Cell Biology and Genetics, Dres-
den, Germany; reference 25) using 5
 

 
-GCAACGGTACCGC-
TCTGTCCATTG-3
 
 
 
and 5
 

 
-CTACTCGAGGTTCTTAAGC-
CGCCA-3
 

 
 and were cloned in KpnI/EcoRI-opened pCD4ext.
For CD4–LDL–CD4, the LDL-R transmembrane domain was
amplified using 5
 

 
-GAGGAATTCCCATAGAAGGAAGAC-3
 

 
as reverse oligonucleotide and the fragment was cloned in
pCD4ext. The CD4 intracellular domain, maintaining the double
acylation sequence and the stop codon, was PCR amplified with
5
 

 
-GAGGAATTCTGTGTCAGGTGCCGG-3
 
 
 
and 5
 

 
-GAC-
CTCGAGTCAAATGGGGCTACA-3
 

 
, and then cloned in
EcoRI/XhoI-digested pCD4ext LDL-R transmembrane vector.
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HEK-293 cells were transfected using a standard calcium phos-
phate method. Transfection efficiency was 74–85%, as deter-
mined with an enhanced green fluorescent protein vector. CD4
levels were maximal 24–96 h after transfection as analyzed by
FACS
 
® 
 
(EPICS; Coulter) using an FITC–anti-CD4 (Immuno-
tech) or an FITC-labeled control antibody. The percentage of
CD4
 
 
 
cells observed after subtracting the control was multiplied
by the average fluorescence intensity to calculate surface CD4 ex-
pression for each mutant (26).
 
Flotation Experiments.
 
HEK-293 cells expressing the CD4
mutants were lysed at 4
 

 
C in TXNE buffer (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100) plus
protease inhibitors. Detergent-resistant membranes (DRMs) were
isolated by ultracentrifugation (170,000 
 
g
 
) for 4 h at 4
 

 
C in a 30–
35% OptiPrep™ gradient (Nycomed; reference 21). Normalized
protein amounts were analyzed by Western blot with anti-CD4
(Leu3A; Becton Dickinson), anti–transferrin receptor (TfR;
Zymed Laboratories), and anti–VIP-21 (Santa Cruz Biotechnol-
ogy, Inc.) antibodies.
 
Immunofluorescence and gp120-induced Patching.
 
For colocaliza-
tion of CD4 with GM1, HEK-293 transfected with CD4 mutants
were incubated for 30 min at 12
 

 
C with anti-CD4 (Leu3A) fol-
lowed by a Cy3-anti–mouse antibody (Jackson ImmunoResearch
Laboratories). Finally, FITC-cholera toxin was added for 5 min at
12
 

 
C.
For gp120 copatching, HEK-293 cells expressing CD4 mu-
tants were incubated with recombinant gp120 (T cell line–
adapted X4 virus, isolate IIIB; Intracel) in PBS/0.2% BSA. Cells
were incubated for 30 min at 12
 

 
C with rabbit polyclonal anti-
gp120, FITC–anti-CD4 (OKT4; Ortho Diagnostics), and bio-
tinylated anti-CXCR4 (FAB172; R&D Systems). Finally,
anti–rabbit Cy3 antibody and streptavidin-Cy5 (Jackson Immu-
noResearch Laboratories) were added.
In all cases, cells were fixed with 3.7% paraformaldehyde in
PBS for 5 min on ice, mounted in Vectashield medium (Vector
Laboratories), and visualized by confocal laser microscopy (Leica).
 
CD4–Lck Association and In Vitro Kinase (IVK) Assays.
 
HEK-
293 cells expressing CD4 and Lck were serum starved for 4 h,
lysed in 50 mM Hepes, pH 8.0, 150 mM NaCl, 1% Triton X-100,
plus phosphatases and proteases inhibitors, and then precipitated
with equal amounts of anti-CD4 (HP2/6; provided by F.
Sánchez-Madrid, Hospital de la Princesa, Madrid, Spain; refer-
ence 27) and agarose-coupled anti–mouse antibody (Sigma-
Aldrich). IVK assays were performed with the pellets using eno-
lase (Sigma-Aldrich) as a substrate (28).
 
CD4-induced Lck Activation.
 
Cells were cotransfected with
CD4 mutants, Lck and CD8
 
 
 
(provided by E.L. Reinherz, Dana-
Farber Cancer Institute, Boston, MA; reference 28). Cells were
serum starved and incubated for 20 min at 4
 

 
C with anti-CD4 and
anti–mouse antibodies (27). Plates were then incubated at 37
 

 
C
for the times indicated and lysed as described above. Equal
amounts (200 
 

 
g) were precipitated with anti-CD8 antibody
(B9.4.2; reference 29) and SDS-PAGE–resolved pellets blotted se-
quentially with peroxidase-coupled antiphosphotyrosine, anti-Lck
COOH-terminal (Upstate Biotechnology), and anti-CD3
 
 
 
(386)
antibodies. IVK assays were performed by the immunoprecipita-
tion of cell lysates with anti-Lck COOH-terminal antibody plus
protein A–Sepharose (Amersham Biosciences) as described above.
 
gp120 Binding Analysis.
 
Mock-transfected or CD4 construct–
transfected HEK-293 cells were incubated sequentially with 10
 

 
g/ml gp120
 
IIIB
 
 and an anti-gp120 antibody, and then with
FITC–anti-CD4 and phycoerythrin-goat anti–rabbit (Caltag) an-
tibodies (all for 30 min at 4
 

 
C) to monitor CD4 expression and
 
gp120 binding, respectively. gp120 binding was analyzed in
CD4
 
 
 
gated cells. Control samples were processed similarly,
omitting gp120.
 
HIVenv-induced Cell–Cell Fusion.
 
HEK-293 cells were cotrans-
fected with the CD4 constructs, the pSCluc plasmid harboring
the firefly luciferase gene under the control of the vaccinia virus
7.5 promoter (provided by D. Rodríguez, Centro Nacional de
Biotecnología, Madrid, Spain), and the promoterless renilla lu-
ciferase plasmid (30). CD4 expression was analyzed 24 h after
transfection by flow cytometry. HIV-1
 
env
 
IIIB 
 
was introduced into
effector HEK-293 cells by infection for 1 h at 37
 

 
C with re-
combinant vaccinia virus. 12 h after infection, 10
 
5 
 
effector cells
cultured in 100 
 

 
g/ml rifampicin were mixed with HEK-
293-CD4–expressing cells for 6 h at 37
 

 
C, and cell–cell fusion
was analyzed by luciferase activity measurement in cell lysates (25
mM Tris-phosphate, pH 7.8, 1% Triton X-100, 1 mM EDTA, 1
mM DTT, 8 mM MgCl
 
2
 
, 15% glycerol). Luciferase activity was
calculated as the quotient between firefly and renilla activity
values.
 
Generation of Recombinant Replication-defective HIV Pseudotypes.
 
For single-round infections, pNL4-3.Luc.R-E- (provided by
N. Landau, AIDS Research and Reference Reagent Program,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda, MD) was pseudotyped with
HIV-1
 
NL4-3
 
 
 
env
 
, HIV-1
 
Ada
 
, and vesicular stomatitis virus
(VSV)-G 
 
env
 
 as previously described (14). HEK-293-CCR5
or MT-2-CCR5 cells (provided by J. Alcamí, Instituto Salud
Carlos III, Madrid, Spain) expressing selected CD4 mutants
were transduced with viral supernatants (1 and 0.1 multiplicity
of infection) for 2 h at 37
 

 
C, and infectivity was determined
after 24 h.
 
Biotinylation of Cells.
 
Mock, CD4wt, or CD4–LDL cells
were biotinylated using EZ-Link Sulfo-NHS-Biotin (Pierce
Chemical Co.) according to the manufacturer’s instructions.
Cells were lysed with RIPA (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxycholate) and equal
amounts (100 
 

 
g) of lysates were precipitated with agarose-avi-
din for 1 h at 4
 

 
C. Pellets were washed and resolved in SDS-
PAGE. Western blots were probed sequentially with anti-6xHis
(Sigma-Aldrich), anti-CD4 (Leu3A), and peroxidase-streptavidin
(Sigma-Aldrich).
 
HIV-1 Infection of MT-2-CCR5 Cells.
 
Mock-, CD4wt-, or
CD4–LDL-transfected MT-2-CCR5 cells were incubated with
NL4-3 or BaL viral stocks (1 or 10 ng p24 antigen/10
 
6 
 
cells) for
2 h at 37
 

 
C. 0.5 
 
 
 
10
 
6
 
/ml cells were cultured in complete RPMI
medium. Cell-free supernatants were collected daily and tested
for p24 antigen (Coulter).
 
Results
 
Generation of CD4 Mutants with Differential Raft Partition-
ing.
 
Double acylation and GPI modification are major
signals for protein partitioning in rafts by anchoring pro-
teins to the inner or outer leaflet of the membrane raft, re-
spectively. Nonetheless, integral membrane proteins have
no clear consensus signal that indicates preferential raft as-
sociation. The best studied raft-associated transmembrane
protein is the influenza hemagglutinin, whose raft targeting
is determined by three acylation acceptor cysteines and spe-
cific amino acids in its transmembrane domain (31, 32).
CD4 has a 26–amino acid transmembrane region with two
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putative palmitoylation acceptor cysteines in the jux-
tamembrane domain (33). We generated a panel of CD4
chimeras and mutants that affect both transmembrane and
cytoplasmic domains (Fig. 1 A). The CD4 extracellular do-
main was fused to the LDL-R transmembrane and jux-
tamembrane region (CD4–LDL). As a control for this con-
struct, a CD4 mutant was generated by replacing the CD4
transmembrane domain with that of the LDL-R (CD4–
LDL–CD4). This mutant retains the palmitoylated cys-
teines. The CD4 ectodomain was also fused to a GPI con-
sensus sequence (CD4–GPI) to target CD4 luminal domain
to rafts. Finally, we generated CD4 mutants, including
three in which palmitoylated Cys
 
394 
 
and/or Cys
 
397 
 
are elim-
inated by alanine scanning of the transmembrane and jux-
tamembrane CD4 domains.
We analyzed raft partitioning of the CD4 mutants by
isolating a DRM fraction enriched in raft-associated pro-
teins (6). HEK-293 cells expressing the CD4 mutants were
extracted with Triton X-100 and the DRM fraction was
isolated in density gradients. A large proportion of CD4wt,
CD4–GPI, and CD4–LDL–CD4 proteins copurify with
caveolin in the DRM fraction, whereas CD4–LDL copuri-
fies with the TfR in the nonraft compartment (Fig. 1 B).
Because CD4–LDL and CD4–LDL–CD4 have identical
 
transmembrane domains, the results suggest that the trans-
membrane sequence does not contain the main determi-
nants for CD4 partitioning in rafts. Supporting this idea, all
CD4 transmembrane mutants showed DRM partitioning
comparable to that of CD4wt (unpublished data). Single
CD4–3A392, CD4–C397A (unpublished data), or double
CD4–C394/397A (Fig. 1 B) palmitoylation mutants also
partition in the DRM fraction, suggesting that CD4 acyla-
tion is not a major determinant for CD4 association
to DRM.
DRM analysis proved useful in identifying parameters
affecting raft partitioning of proteins, although weak raft as-
sociations might be lost after detergent extraction (6).
These misinterpretations can be avoided in copatching ex-
periments, as antibody-induced lateral clustering stabilizes
protein–lipid interactions. We analyzed raft partitioning of
the CD4 constructs in live HEK-293 cells by copatching
CD4 and the cholera toxin 
 

 
 subunit, which binds to the
raft-associated ganglioside GM1. Confocal analysis indi-
cated that CD4wt (Fig. 1 C), CD4–GPI (Fig. 1 D), CD4–
LDL–CD4 (Fig. 1 F), the palmitoylation CD4–C394/
397A mutant (Fig. 1 G), as well as the transmembrane CD4
mutants (unpublished data), colocalize extensively with
GM1. Conversely, CD4–LDL and GM1 show segregated
staining patterns (Fig. 1 E), confirming that this chimera
does not partition in rafts.
 
Partitioning of the CD4 Ectodomain in Rafts Is Sufficient to
Activate LCK.
 
We studied CD4 chimera and mutant as-
sociation to, and activation of, raft-p56
 
lck
 
. Lck association
with the palmitoylation-deficient CD4 mutants was re-
ported (33), which suggests that neither the CD4 trans-
membrane nor juxtamembrane domain plays a role in Lck
activation. Accordingly, chimeras with the CD4 cytoplas-
mic domain bind to Lck in cotransfected HEK-293 cells
independently of the transmembrane domain (Fig. 2 A).
Because CD4–GPI and CD4–LDL do not associate with
Lck directly (Fig. 2 A), they were used to analyze CD4 par-
titioning effects on Lck activation. HEK-293 cells were
cotransfected with the CD4 constructs, p56
 
lck
 
, and a chi-
meric protein composed of the CD8 extramembrane and
transmembrane domains fused to the CD3
 
 
 
chain (CD8
 

 
;
reference 28), an Lck substrate (34). Cross-linking of CD4–
GPI induces Lck association with CD8
 

 
 in a time-depen-
dent manner and also induces an increase in CD8
 
 
 
tyrosine
phosphorylation (Fig. 2 B). This is not observed in cells ex-
pressing the nonraft CD4–LDL chimera. Furthermore,
CD4–GPI cross-linking increases Lck activity in anti-Lck
immunoprecipitates, as measured by IVK assays (Fig. 2 C).
Again, CD4–LDL cross-linking produces no detectable in-
crease in Lck activity (Fig. 2 C). These results suggest that if
the CD4 extracellular domain is located in rafts, the cyto-
plasmic CD4 domain is not necessary to activate Lck. Both
Lck recruitment to CD8
 
 
 
and Lck activation are more ro-
bust in CD4wt– (Fig. 2, B and C) or CD4–LDL–CD4–
cross-linked cells (unpublished data) than in CD4–GPI
cells, which suggests that prior Lck interaction with the
CD4 cytoplasmic tail enhances subsequent binding to tar-
gets and kinase activation.
Figure 1. Partitioning of CD4 mutants into distinct membrane do-
mains. (A) The scheme shows the amino acid sequence of the CD4 mu-
tants generated. Mutations or foreign sequences added to the CD4 extra-
cellular domain are indicated in bold. (B) HEK-293 cells expressing CD4
mutants were fractionated in flotation gradients and CD4 partitioning was
analyzed by Western blot. Fraction 1 represents the top and fraction 5
represents the bottom of the gradient. Filters were hybridized with anti-
TfR and anti-VIP21 (caveolin-1) as controls for nonraft- and raft-associ-
ated proteins, respectively. (C–G) Confocal microscopy of CD4 mutant–
expressing cells stained with cholera toxin  subunit (green) and anti-CD4
antibody (red). Yellow staining indicates colocalization of the mole-
cules. The two-color overlay shows the representative cells for (C)
CD4wt, (D) CD4–GPI, (E) CD4–LDL, (F) CD4–LDL–CD4, and (G)
CD4–C394/397A (n 	 50/mutant). Bar, 5 m.
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Exclusion of CD4 Extracellular Domain from Raft Domains
Impedes HIV-1 Entry. We analyzed whether raft parti-
tioning of CD4 affects its HIV-1 receptor function. We
confirmed that gp120 binding was comparable among the
distinct CD4 mutants (Fig. 3 A), indicating that chimeric
domains do not affect correct CD4 ectodomain folding.
No significant gp120 binding was detected in nontrans-
fected cells (unpublished data). The CD4 constructs were
tested in a luciferase-based, HIV-1envIIIB–mediated cell–cell
fusion assay. Because HIV-1–induced fusion is receptor
density dependent (35), a DNA concentration range was
used to confirm similar mutant CD4 cell surface expression
(Fig. 3 B). HEK-293Env–HEK-293CD4 fusion increases
luciferase activity at comparable levels in raft-associated
CD4wt, CD4–GPI, CD4–LDL–CD4 (Fig. 3 C), and the
transmembrane and juxtamembrane mutant-expressing
cells (unpublished data). Nonetheless, fusion is completely
abrogated in cells expressing nonraft CD4–LDL (Fig. 3 C).
CD4–LDL and CD4–LDL–CD4 share an identical trans-
membrane domain, indicating that the inserted LDL frag-
ment does not influence Env-mediated fusion. As efficient
HIV-1–mediated fusion occurs in cells expressing CD4–
GPI, the lack of HIV-1 fusion in CD4–LDL cells is proba-
bly due to partitioning of this mutant in a nonraft mem-
brane fraction.
To analyze the effect of CD4 partitioning on viral entry,
we performed single-round infections with a replication-
defective HIV-1 NL4-3 variant pseudotyped with HIV-X4
(NL4-3), HIV-R5 (Ada), or VSV-G envelopes. HEK-
293–CCR5 cells, an established cell line expressing CCR5
at high levels, were used as targets. Efficient viral entry was
observed in all raft-associated CD4 mutants, whereas cells
expressing the nonraft CD4–LDL mutant were refractory
to infection by either X4- or R5-pseudotyped HIV-1 vari-
ants (Fig. 3 D). CD4–LDL cells are nonetheless infected by
VSV envelope-pseudotyped NL4-3 variants (Fig. 3 D),
which indicates that raft partitioning of CD4 is a specific
requisite for HIV-1 entry. Although CD4–LDL drastically
affects X4 and R5 virus entry, we found that the inhibitory
effect of the nonraft CD4–LDL mutant is more dramatic
for X4 enveloped viruses than for the R5 pseudotypes.
This difference may be the consequence of the high, non-
physiological CCR5 levels expressed by this cell line. In-
deed, coreceptor density has been shown to influence both
HIV-1 infectivity and entry inhibitor sensitivity (36, 37).
CD4 Partitioning in Rafts Is Required for gp120-induced Re-
ceptor Clustering. According to the raft hypothesis, CD4–
LDL may not support HIV-1 entry, as the CD4–gp120
coreceptor fusion complex cannot be formed. Using con-
focal microscopy, we analyzed the ability of selected CD4
mutants to form high order molecular complexes of gp120,
CD4, and CXCR4. We observed gp120-induced patches
in cells expressing raft-associated CD4wt (Fig. 4 A), CD4–
GPI (Fig. 4 B), and CD4–LDL–CD4 (Fig. 4 C), in which
gp120 (red), CXCR4 (blue), and CD4 (green) colocalize
(white staining). Conversely, in CD4–LDL-expressing
cells, anti–gp120-induced patching promotes small aggre-
gates of gp120 and CD4 (yellow) that do not colocalize
with CXCR4 (Fig. 4 D). Thus, when gp120–CD4 com-
plexes are formed in rafts, anti–gp120-induced clustering
may trigger lateral coalescence of CD4–gp120- and
CXCR4-bearing rafts, resulting in the assembly of gp120,
Figure 2. Raft partitioning,
but not association, is a requisite
for CD4-induced Lck activation.
(A) HEK-293 cells coexpressing
the indicated mutants and Lck
were anti-CD4 precipitated.
CD4-associated tyrosine kinase
activity was determined in an
IVK assay using enolase as a sub-
strate. The migration of both
Lck and enolase is indicated by
arrows. (B) HEK-293 cells coex-
pressing Lck, CD8 and CD4wt,
and CD4–GPI or CD4–LDL
were incubated with anti-CD4
for the times indicated. Addi-
tional cross-linking was induced
with a secondary anti–mouse an-
tibody. After lysis, anti-CD8
immunoprecipitates were blotted
sequentially with antiphosphoty-
rosine (PY), anti-Lck, and anti-
CD3 antibodies as indicated.
CD4, Lck, and CD8 expression
levels for each condition were
determined by Western blot. (C)
IVK assay of anti-Lck immuno-
precipitates from lysates in B.
Results represent two indepen-
dent experiments.
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CD4, and CXCR4 complexes. However, CD4–LDL–
gp120 complexes formed in nonraft membranes will not
trigger coalescence of CXCR4-containing rafts, resulting
in the inability of this mutant to form CD4–gp120–
CXCR4 complexes. These results suggest that CD4 parti-
tioning in membrane rafts is necessary for the CD4–gp120–
CXCR4 complex formation.
Nonraft CD4–LDL Prevents HIV-1 Infection in CD4 T
Cells. The immunofluorescence results provide a molecu-
lar basis to explain why the nonraft CD4–LDL mutant does
not support HIV-1 entry. As this mutant binds to HIV-
1Env, we examined whether CD4–LDL prevents HIV-1
infection of CD4 cells. The MT-2-CCR5 cell line ex-
presses CD4 as well as CXCR4 and CCR5 coreceptors,
rendering it susceptible to infection by X4 and R5 viral
strains (14). Therefore, we transfected MT-2-CCR5 cells
with the nonraft CD4–LDL mutant. A transfection effi-
ciency of 44 
 7% was estimated using a green fluorescent
protein reporter plasmid. We analyzed ectopic cell surface
CD4 expression by the biotinylation of mock-, CD4wt-
and CD4–LDL-transfected MT-2-CCR5 cells. CD4–LDL
has a 6xHis tag. Anti-6xHis antibody detects a specific band
in avidin-precipitated cell lysates (Fig. 5 A), indicating that
CD4–LDL is biotinylated and therefore expressed on the
surface of these cells. The total CD4 levels in these blots
confirm ectopic CD4wt expression (Fig. 5 A).
Productive HIV-1 infection was examined daily by re-
cording p24 levels in mock-, CD4wt-, or CD4–LDL-
expressing MT-2-CCR5 cells infected with NL4-3 (X4) or
BaL (R5) strains. CD4–LDL expression delays p24 kinetics
compared with mock- or CD4wt-expressing cells (Fig. 5
B) independently of the viral strain tested. This suggests
Figure 3. The nonraft CD4–LDL mutant does not allow HIV-1 entry.
(A) HEK-293 cells expressing CD4 chimeras were incubated alone (filled)
or with recombinant gp120 (open). Anti-gp120 antibody fluorescence in-
tensity was then recorded in the CD4 gated cells by flow cytometry.
The percentage of gp120-binding CD4 cells is indicated in each panel. A
representative experiment is shown (n 	 3). (B) HEK-293 cells were
transfected with different amounts of cDNA as indicated, and CD4 immu-
noreactivity on the cell surface was analyzed by flow cytometry. Cell sur-
face levels of CD4 were calculated by multiplying the percentage of
CD4 cells and the mean fluorescence intensity for each condition. Data
represent the mean 
 SD of duplicate points (n 	 4). (C) The cells in B
were mixed with HIV-1IIIBenv–expressing HEK-293 cells and cell–cell
fusion events were measured. Luciferase activity values were normalized
using a promoterless renilla plasmid. (D) Single-round infection experi-
ments were performed in HEK-293-CCR5 cells expressing the indicated
CD4 mutants using a replication-defective NL4-3 virus pseudotyped with
HIVNL4–3 (solid bar), HIVAda (gray bar), or VSV-G (open bar) envelopes.
Cell infection, detected as an increase in luciferase activity, was normal-
ized considering CD4wt as 100%. Data represent mean 
 SD of duplicate
points (n 	 4).
Figure 4. Raft partitioning of the CD4 extracellular domain is required
for gp120-induced lateral association of CD4 and CXCR4. HEK-293
cells expressing (A and A) CD4wt, (B and B) CD4–GPI, (C and C)
CD4–LDL–CD4, and (D and D) CD4–LDL were incubated with re-
combinant gp120IIIB and copatched with anti-gp120 (red), anti-CD4
(green), and anti-CXCR4 (blue) as indicated, and then analyzed by con-
focal microscopy. The three-color overlay is shown in the merge panel.
Representative cells are shown (n 	 50–60/mutant). Bar, 5 m.
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that the nonraft CD4–LDL mutant inhibits HIV-1 infec-
tion of CD4 cells. We explored this inhibitory effect in
single-round infection experiments. Mock-, CD4wt-, or
CD4–LDL-expressing MT-2-CCR5 cells were exposed to
a replication-defective NL4-3 HIV-1–pseudotyped virus.
The infection ratio of MT-2–CD4–LDL cells with this
HIV-1 variant was 60% lower than that observed in mock
or CD4wt cells, which again indicates that the CD4–LDL
mutant impairs HIV-1 entry in MT-2-CCR5 cells.
Discussion
HIV-1 entry is a multistep process that requires virus at-
tachment to the cell surface via CD4, an essential interac-
tion with a coreceptor to trigger conformational changes in
the viral fusion protein, and the viral–cell membrane fusion
reaction itself. The use of drugs to sequester membrane
cholesterol or inhibit GSL synthesis provided indirect evi-
dence that these entry steps are unlikely to occur at random
on the cell surface, but are confined to specific membrane
regions termed rafts (14–18). The primary finding in this
study is that CD4 partitioning into raft domains is critical
for its function as an HIV receptor, as well as for CD4-
mediated signaling, two independent CD4 processes. By en-
gineering the transmembrane and cytoplasmic CD4 domains,
we generated the nonraft CD4–LDL mutant that retains
HIV-1–binding capacity, but does not allow viral infection
by blocking viral entry. These results provide direct evi-
dence that HIV-1 exploits raft domains on the host plasma
membrane as entry sites into the cell.
Earlier studies indicated that the cytoplasmic, transmem-
brane, or juxtamembrane regions are not needed for CD4
function as an effective HIV-1 receptor (38, 39). Concur-
ring with this, we found that the CD4–GPI mutant medi-
ates HIV-1 entry as efficiently as CD4wt. Even though this
mutant cannot directly interact with Lck, CD4–GPI cross-
linking induces Lck activation, further suggesting that CD4
cytoplasmic and transmembrane domains are unnecessary
for CD4-mediated signal transduction. It is not known how
GPI-anchored proteins communicate with the intracellular
milieu, although GPI-induced signaling is thought to de-
pend on the raft structure in membranes (2). Because rafts
normally contain few molecules, the clustering of GPI-
anchored proteins would cause small rafts to coalesce, bring-
ing raft-associated transmembrane proteins into proximity. Al-
ternatively, the clustering of GPI-anchored proteins may
induce transmembrane protein recruitment to rafts, which
may function as adaptors between GPI proteins and intracel-
lular kinases (2). In contrast to CD4–GPI, the nonraft CD4–
LDL mutant, which also lacks CD4 transmembrane and
cytoplasmic domains, does not activate Lck and cannot medi-
ate HIV-1 infection. These results suggest that CD4 extra-
cellular domain location in rafts is the major determinant of
CD4 function in mediating signaling and viral infection.
Nevertheless, the potential role of cytoplasmic and/or
transmembrane domains in determining CD4 association to
rafts remains an open question. The affinity of a membrane
protein for rafts can be increased by oligomerization, acyla-
tion, coupling to a raft-associated molecule, or conforma-
tional changes in a transmembrane region (6). The muta-
tion of specific amino acids in the transmembrane domain,
replacement of the membrane-spanning region with that of
the LDL-R, or the elimination of the acylation acceptor
cysteines is insufficient to force CD4 partitioning to nonraft
regions. Comparison of CD4–LDL–CD4 and the CD4–
LDL mutants suggests that the CD4 cytoplasmic domain
exercises considerable influence on CD4 association to
rafts, for instance, by enabling interaction with p56lck. This
is nonetheless unlikely, as CD4–LDL–CD4 is also raft asso-
ciated, even in the absence of Lck expression. Oligomer-
ization is an important determinant of transmembrane pro-
tein partitioning in rafts. Proteins such as LDL-R, which
does not partition in rafts by DRM criteria, are partially raft
associated after oligomerization (3). Cross-linking with
anti-CD4 does not increase raft partitioning of the CD4–
LDL mutant, however, which lacks the cytoplasmic LDL-
Figure 5. Expression of the nonraft CD4–LDL mutant prevents HIV-1
entry in CD4 cells. (A) Mock-, CD4wt-, or CD4–LDL-transfected
MT-2-CCR5 cells were biotinylated to analyze cell surface CD4 ex-
pression. Biotin-labeled proteins were precipitated with agarose-coupled
avidin and sequentially blotted with anti-6xHis and anti-CD4 antibodies.
Total biotinylated proteins in the same immunoprecipitates were devel-
oped with avidin. (B) The cells in A were exposed to R5 (BaL) or X4
(NL4-3) HIV-1 viral strains at the indicated doses and productive infec-
tion followed by measurement of p24 antigen levels. Data shown are
mean 
 SD of triplicate points (n 	 3). , mock; , CD4wt; , CD4–
LDL. (C) Mock-, CD4wt-, and CD4–LDL-expressing MT-2-CCR5
cells were infected with a HIVNL4–3env-pseudotyped replication-defective
NL4-3 virus. Infected cells were determined 24 h later by measuring lu-
ciferase activity. Data are mean 
 SD (n 	 4).
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R region. This differential raft partitioning by LDL-R and
CD4–LDL may explain the HIV-1 infection described in
cells expressing a CD4–LDL-R chimera (38), whereas our
CD4–LDL mutant fails to support viral infection. A final,
intriguing possibility is that multiple determinants in the
cytoplasmic, transmembrane, or even in the extracellular
domain of CD4 are responsible for drawing CD4 into
membrane rafts. Decoding the molecular signals that trig-
ger CD4 association to rafts warrants additional research.
The most striking finding in this study is that the nonraft
CD4–LDL mutant hinders infection by X4 and R5 viruses
in a CD4 MT-2 cell line. This inhibition probably occurs
at initial phases of infection, as CD4–LDL also prevents
MT-2 infection by a replication-deficient virus variant.
The true inhibitory ability of the CD4–LDL mutant on
HIV-1 infection is nonetheless difficult to assess based on
the experiments presented here. First, only 40% of the
MT-2-CCR5 cells are transfected by the nonraft mutant.
Second, CD4–LDL expression would decrease throughout
the spreading infection, as cell expression of this mutant is
not selected during the experimental period. These two
features may cause underestimation of the inhibitory capac-
ity of CD4–LDL on spreading and single-round HIV-1 in-
fection of CD4 cells. We are currently generating stable
cell lines expressing distinct CD4wt/CD4–LDL ratios.
A mechanism by which CD4–LDL inhibits HIV-1 in-
fection may be postulated from the observation that the
formation of high order complexes between gp120 and cell
receptors is impaired in cells expressing the nonraft CD4–
LDL mutant. The plasma membrane is probably in dy-
namic equilibrium between domains in raft and nonraft
phases, which may preclude or predispose to protein–pro-
tein interactions. CD4–LDL may therefore be unable to
mediate HIV-1 entry, as the CD4–Env complexes formed
in a nonraft membrane fraction cannot further interact with
coreceptors. This mechanism may also operate in CD4
MT-2 cells, suggesting that CD4–LDL acts as a competi-
tive inhibitor by preventing HIVEnv interaction with “fu-
sion-competent” CD4 molecules on the cell surface. Al-
ternatively, gp120 binding to CD4–LDL in a nonraft
environment may prevent viral interaction with other host
cofactors involved in HIV-1 entry. The GSL may act as al-
ternative HIV-1 entry cofactors, due to their direct, CD4-
dependent association with the viral envelope (17, 18, 40).
Because rafts are GSL-enriched, such an interaction would
not occur in cells expressing nonraft CD4–LDL. Finally, it
is also possible that CD4–LDL binding to gp120 outside
rafts cannot promote the conformational changes in the vi-
ral Env protein necessary for coreceptor binding. If this is
the case, CD4–LDL partitioning in nonraft membranes
would again be the major cause of this failure, as the raft-
associated CD4–LDL–CD4 mutant, which also has the
LDL-R transmembrane domain, efficiently mediates the
formation of ternary CD4–gp120 coreceptor complexes.
In light of this study and reports showing the importance
of lipid components in HIV budding (41, 42), it is tempt-
ing to speculate that the manipulation of specific host
membrane raft components would be useful in designing
new strategies to prevent and/or block HIV-1 infection.
These therapeutic approaches would be suitable for both
X4 and R5 viral strains and would obviate the problem of
resistance mutants observed using current treatments.
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